Atherosclerosis: Cell biology and lipoproteins

Current Opinion in Lipidology

Volumn 21, Issue 1, 2010, Pages 97-98

  Wigren, Maria ^a   Björkbacka, Harry ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CYTOKINE; F ACTIN; FIBRONECTIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE SYK; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; CORONARY ARTERY; CYTOLOGY; FOAM CELL; HUMAN; HYPERLIPIDEMIA; INNATE IMMUNITY; MONOCYTE; NONHUMAN; NOTE; OXIDATION; PERITONEUM MACROPHAGE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS; MICE; T-LYMPHOCYTES, HELPER-INDUCER; TOLL-LIKE RECEPTOR 4;

EID: 77649088857     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283353891     Document Type: Note

References (23)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
2. Miller YI, Viriyakosol S, Worrall DS, et al. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. ArteriosclerThromb Vasc Biol 2005; 25:1213-1219.
3. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6:823-835.
4. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10:416-421.
5. Michelsen KS, Wong MH, Shah PK, et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101:10679-10684.
6. Miller YI, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278:1561-1568.
7. Stoletov K, Fang L, Choi SH, et al. Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ Res 2009; 104:952-960.
8. Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macro- phages via toll-like receptor-4-dependent fluid phase uptake. Circ Res 2009; 104:1355-1363.
9. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009; 104:210-218; 21p following 218.
10. Coenen KR, Gruen ML, Lee-Young RS, et al. Impact of macrophage toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice. Diabetologia 2009; 52:318-328.
11. Hwang D. Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through toll-like receptor 4-derived signaling pathways. Faseb J 2001; 15:2556-2564. (Pubitemid 33131082)
12. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116:3015-3025.
13. Schaeffler A, Gross P, Buettner R, et al. Fatty acid-induced induction of tolllike receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009; 126:233-245.
14. Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Tolllike receptor signaling. Arterioscler Thromb Vasc Biol 2009; 29:1944-1949.
15. Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009; 23:265-276.
16. Ji YY, Liu JT, Liu N, et al. PPARalpha activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway. Biochem Pharmacol 2009; 78:1186-1197.
17. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22:1257-1266.
18. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:612-616.
19. JJ, Gaffen SL. Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 2008; 13:170-177.
20. van EsT, van PuijveldeGH, Ramos OH, et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009; 388:261-265.
21. Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009; 206:2067-2077.
22. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119:1424-1432.
23. Xie JJ, Wang J, Tang TT, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice Th17/Treg imbalance in atherogenesis. Cytokine 2009 [Epub ahead of print]. doi: 10.101 6/j.cyto.2009.09.007.